Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS

G J Ossenkoppele¹, D A Breems², G Stuessi³, Y van Norden⁴, M Bargetzi⁵, B J Biemond⁶, P A von dem Borne⁷, Y Chalandon⁸, J Cloos⁹, D Deeren¹⁰, M Fehr¹¹, B Gjertsen¹², C Graux¹³, G Huls¹⁴, J J J W Janssen⁹, A Jaspers¹⁵, M Jongen-Lavrencic¹⁶, E de Jongh¹⁷, S K Klein¹⁸, M van der Klift¹⁹, M van Marwijk Kooy²⁰, J Maertens²¹, L Michaux²², M W M van der Poel²³, A van Rhenen²⁴, L Tick²⁵, P Valk¹⁵, M C Vekemans²⁶, W J F M van der Velden²⁷, O de Weerdt²⁸, T Pabst²⁹, M Manz³⁰, B Löwenberg¹⁵; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK)

Collaborators, Affiliations

Collaborators

Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK):
D A Breems, Havelange, M-C Vekemans, I Moors, F van Obberg, J A Maertens, B Hodossy, S Vansteenweghen, L Lammertijn, D Deeren, C Graux, A Sonet, A Triffet, B T Gjertsen, M Bargetzi, J Passweg, D Heim, San Giovanni, Georg Stuessi, T Pabst, D Betticher, Y Chalandon, O Spertini, M Gregor, U Hess, M Fehr, M G Manz, S K Klein, B J Biemond, G J Ossenkoppele, A van de Loosdrecht, J J W M Janssen, J W J van Esser, M Van der Klift, R E Brouwer, D Van Lammeren-Venema, M D Levin, L W Tick, M C J C Legdeur, G Huls, E Vellenga, M Hoogendoorn, J H Veelken, P A von dem Borne, H C Schouten, O de Weerdt, W J F M van der Velden, J Cornelissen, M Jongen-Lavrencic, B Wouters, H G M Raaijmakers, B Löwenberg, J Kuball, A Van Rhenen, M Van Marwijk Kooy

Affiliations

¹ Amsterdam University Medical Cente, location VUMC, Amsterdam, Netherlands. g.ossenkoppele@amsterdamumc.nl.
² Netwerk Antwerpen, Antwerp, Belgium.
³ Bellinzona-IOSI, Bellinzona, Switzerland.
⁴ HOVON Data Center, Erasmus MC-Department of Hematology, Rotterdam, The Netherlands.
⁵ Aarau-Kantonsspital, Aarau, Switzerland.
⁶ Amsterdam University Medical Center, location AMC, Amsterdam, Netherlands.
⁷ Leiden University Medical Center, Leiden, Netherlands.
⁸ University Hospital and University of Geneva, Genève, Switzerland.
⁹ Amsterdam University Medical Cente, location VUMC, Amsterdam, Netherlands.
¹⁰ Roeselare-AZ Delta, Roeselare, Belgium.
¹¹ St Gallen-Kantonnsspital, St. Gallen, Switzerland.
¹² Haukeland University Hospital, Bergen (N), Norway.
¹³ Yvoir-MontGodinne, Yvoir, Belgium.
¹⁴ University Medical Center, Groningen, Netherlands.
¹⁵ Hôpital Citadelle, Liège (B), Belgium.
¹⁶ Erasmus University Medical Center, Rotterdam, Netherlands.
¹⁷ Dordrecht ASZ, Dordrecht, Netherlands.
¹⁸ Meander Medical Center, Amersfoort, Netherlands.
¹⁹ Amphia-Breda, Breda, Netherlands.
²⁰ Isala Hospital, Zwolle, Netherlands.
²¹ Hospital Gasthuisberg, Leuven (B), Belgium.
²² Center for Human Genetics, KU Leuven and University Hospitals Leuven, Leuven, Belgium.
²³ Maastricht University Medical Center, Maastricht, Netherlands.
²⁴ UMC Utrecht, Utrecht, Netherlands.
²⁵ MaximaMC Eindhoven, Eindhoven, Netherlands.
²⁶ Hôpital St Luc, Bruxelles, Belgium.
²⁷ Radboudumc Nijmegen, Nijmegen, Netherlands.
²⁸ St Antonius Hospital, Nieuwegein, Netherlands.
²⁹ Department of Oncology, University Hospital, Inselspital and University of Bern, Bern, Switzerland.
³⁰ University Hospital, Zurich, Switzerland.

PMID: 32733013
DOI: 10.1038/s41375-020-0994-7

Published Erratum

Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS

G J Ossenkoppele et al. Leukemia. 2020 Oct.

. 2020 Oct;34(10):2820.

doi: 10.1038/s41375-020-0994-7.

Authors

Collaborators

Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK):
D A Breems, Havelange, M-C Vekemans, I Moors, F van Obberg, J A Maertens, B Hodossy, S Vansteenweghen, L Lammertijn, D Deeren, C Graux, A Sonet, A Triffet, B T Gjertsen, M Bargetzi, J Passweg, D Heim, San Giovanni, Georg Stuessi, T Pabst, D Betticher, Y Chalandon, O Spertini, M Gregor, U Hess, M Fehr, M G Manz, S K Klein, B J Biemond, G J Ossenkoppele, A van de Loosdrecht, J J W M Janssen, J W J van Esser, M Van der Klift, R E Brouwer, D Van Lammeren-Venema, M D Levin, L W Tick, M C J C Legdeur, G Huls, E Vellenga, M Hoogendoorn, J H Veelken, P A von dem Borne, H C Schouten, O de Weerdt, W J F M van der Velden, J Cornelissen, M Jongen-Lavrencic, B Wouters, H G M Raaijmakers, B Löwenberg, J Kuball, A Van Rhenen, M Van Marwijk Kooy

Affiliations

¹ Amsterdam University Medical Cente, location VUMC, Amsterdam, Netherlands. g.ossenkoppele@amsterdamumc.nl.
² Netwerk Antwerpen, Antwerp, Belgium.
³ Bellinzona-IOSI, Bellinzona, Switzerland.
⁴ HOVON Data Center, Erasmus MC-Department of Hematology, Rotterdam, The Netherlands.
⁵ Aarau-Kantonsspital, Aarau, Switzerland.
⁶ Amsterdam University Medical Center, location AMC, Amsterdam, Netherlands.
⁷ Leiden University Medical Center, Leiden, Netherlands.
⁸ University Hospital and University of Geneva, Genève, Switzerland.
⁹ Amsterdam University Medical Cente, location VUMC, Amsterdam, Netherlands.
¹⁰ Roeselare-AZ Delta, Roeselare, Belgium.
¹¹ St Gallen-Kantonnsspital, St. Gallen, Switzerland.
¹² Haukeland University Hospital, Bergen (N), Norway.
¹³ Yvoir-MontGodinne, Yvoir, Belgium.
¹⁴ University Medical Center, Groningen, Netherlands.
¹⁵ Hôpital Citadelle, Liège (B), Belgium.
¹⁶ Erasmus University Medical Center, Rotterdam, Netherlands.
¹⁷ Dordrecht ASZ, Dordrecht, Netherlands.
¹⁸ Meander Medical Center, Amersfoort, Netherlands.
¹⁹ Amphia-Breda, Breda, Netherlands.
²⁰ Isala Hospital, Zwolle, Netherlands.
²¹ Hospital Gasthuisberg, Leuven (B), Belgium.
²² Center for Human Genetics, KU Leuven and University Hospitals Leuven, Leuven, Belgium.
²³ Maastricht University Medical Center, Maastricht, Netherlands.
²⁴ UMC Utrecht, Utrecht, Netherlands.
²⁵ MaximaMC Eindhoven, Eindhoven, Netherlands.
²⁶ Hôpital St Luc, Bruxelles, Belgium.
²⁷ Radboudumc Nijmegen, Nijmegen, Netherlands.
²⁸ St Antonius Hospital, Nieuwegein, Netherlands.
²⁹ Department of Oncology, University Hospital, Inselspital and University of Bern, Bern, Switzerland.
³⁰ University Hospital, Zurich, Switzerland.

PMID: 32733013
DOI: 10.1038/s41375-020-0994-7

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

PubMed Disclaimer

Erratum for

Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS.
Ossenkoppele GJ, Breems DA, Stuessi G, van Norden Y, Bargetzi M, Biemond BJ, A von dem Borne P, Chalandon Y, Cloos J, Deeren D, Fehr M, Gjertsen B, Graux C, Huls G, Janssen JJJW, Jaspers A, Jongen-Lavrencic M, de Jongh E, Klein SK, van der Klift M, van Marwijk Kooy M, Maertens J, Michaux L, van der Poel MWM, van Rhenen A, Tick L, Valk P, Vekemans MC, van der Velden WJFM, de Weerdt O, Pabst T, Manz M, Löwenberg B; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK). Ossenkoppele GJ, et al. Leukemia. 2020 Jul;34(7):1751-1759. doi: 10.1038/s41375-020-0725-0. Epub 2020 Feb 4. Leukemia. 2020. PMID: 32020044 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS

Collaborators

Affiliations

Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS

Authors

Collaborators

Affiliations

Abstract

Erratum for

Publication types

LinkOut - more resources

Full Text Sources

Research Materials

Miscellaneous